

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

13th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI LODR Regulations”).

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that through a Binding Offer dated February 13, 2026, M/s. Alkem Medtech Private Limited (“**Alkem Medtech**”) has offered to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG (“**Occlutech**”) from certain of the Occlutech’s current shareholders for cash consideration (“**Proposed Acquisition**”). Alkem Medtech is a private limited company incorporated in India and a wholly-owned subsidiary of the Company.

For giving effect to the Proposed Acquisition, Alkem Medtech proposes to enter into a Share Purchase Agreement with inter alia the selling shareholders of Occlutech and a Shareholders Agreement with inter alia the continuing shareholders of Occlutech. The Proposed Acquisition is expected to be completed on or before 30th June, 2026 or such other date as may be mutually agreed between the parties, subject to customary conditions to closing.

In this regard, the necessary information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations and Part A of Schedule III of the aforesaid regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure I.

A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

Particulars	Remarks
<p>Name of the target entity, details in brief such as size, turnover etc.:</p>	<p>(i) Name of the Target entity: M/s. Occlutech Holding AG (“Occlutech”)</p> <p>(ii) Details of Target entity: Occlutech is a Swiss limited liability Company incorporated in Switzerland with the corporate registration number CHE - 101329851. Occlutech Group is engaged in the business of inter alia developing, manufacturing, and marketing minimally invasive cardiac implants and accessories for the treatment of congenital heart defects, stroke prevention, and heart failure.</p> <p>(iii) For the period January - December 2024</p> <p>Turnover: EUR 43.95 Mn (INR 397.80 Cr)</p> <p>PAT: EUR Loss 20.52 Mn (Loss INR 185.73 Cr)</p> <p>Networth as on 31 December, 2024: Negative EUR 3.58 Mn (Negative INR 31.93 Cr)</p> <p><i>(Ex rate EUR/INR: Closing 31 December, 2024 – 89.20, 12 months Average 31 December, 2024 – 90.51)</i></p> <p>Estimated numbers for the period January - December 2025</p> <p>Turnover: EUR 49.38 Mn (INR 487.87 Cr)</p> <p>EBITDA: EUR 2.10 Mn (INR 20.79 Cr)</p> <p>PAT: Loss EUR 6.85 Mn (Loss INR 67.65 Cr)</p> <p><i>(Ex rate EUR/INR: 12 months Average 31 December, 2025 –98.80)</i></p>
<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “Arms-length”</p>	<p>The Proposed Acquisition does not constitute a related party transaction.</p> <p>None of the promoters / promoter group / group companies of the Company have any interest in Occlutech.</p>
<p>Industry to which the entity being acquired belongs</p>	<p>Healthcare (Medical device)</p>

ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

<p>Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)</p>	<p>The Proposed Acquisition enables an entry of the Company (through its wholly-owned subsidiary Alkem MedTech Private Limited) into the advanced cardiovascular devices business segment. Occlutech has global presence supported by an extensive distribution network and a portfolio of high-quality products that adhere to the highest regulatory and quality standards. Its reach is expected to expand further through robust product development.</p>
<p>Brief details of any governmental or regulatory approvals required for the acquisition</p>	<p>The Proposed Acquisition is subject to foreign direct investment clearances to be obtained in Italy and Sweden and a precautionary filing in France.</p>
<p>Indicative time period for completion of the acquisition</p>	<p>30th June, 2026 or such other date as may be mutually agreed between the parties.</p>
<p>Consideration- whether cash consideration or share swap or any other form and details of the same</p>	<p>Cash consideration</p>
<p>Cost of acquisition and/or the price at which the shares are acquired;</p>	<p>Total Equity value is EUR 180.70 million. The Proposed Acquisition is up to 55% of the total outstanding equity shares of Occlutech.</p>
<p>Percentage of shareholding / control acquired and/or number of shares acquired;</p>	<p>At least 51% and up to 55% of the total issued equity share capital of Occlutech.</p>
<p>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</p>	<p>Brief Background: Occlutech was incorporated in 2000, and is domiciled in Switzerland. Over a period of time, Occlutech has developed, produced, and commercialized first-class, minimally invasive, cardiac implants for Congenital Heart Disease, Stroke Prevention, and Heart Failure, all with the mission to improve patients' lives and address unmet medical needs. Occlutech derives its revenue from various geographies such as Germany, France, Italy, United Kingdom, Spain, Japan and recently entered the United States of America.</p> <p>Date of Incorporation: December 12, 2000 Country: Switzerland Turnover as on last 3 years: December 31, 2024: Eur 43.95 Mn (INR 397.80 Cr) December 31, 2023: Eur 36.24 Mn (INR 324.28 Cr) December 31, 2022: Eur 31.84 Mn (INR 263.41 Cr)</p> <p><i>(Ex-rate 12 months average EUR/INR: 31 December 2022 – 82.73, 31 December, 2023 – 89.48, 31 December, 2024 – 90.51)</i></p> <p><i>(source for exchange rate: https://fedai.org.in/RevaluationRates.aspx?Cid=1&SCid=0&SSCid=0)</i></p>